Funding for this research was provided by:
National Institutes of Health (K24DA034621, DA036927, DA048063, R37DA013806, K23DA041294, R01DA16065, P30AI094189, U01DA036935)
Johns Hopkins University (Doris Duke Early Clinician Investigator Award)
Received: 3 June 2020
Accepted: 27 October 2020
First Online: 10 November 2020
Ethics approval and consent to participate
: The study was conducted in accordance with provisions of the Declaration of Helsinki. It was approved by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board (H.34.01.11.19. A1.). All participants provided written informed consent prior to inclusion in this study.
: Not applicable.
: MS has the following disclosures:• PI for research grants: Funds paid to Johns Hopkins University: AbbVie, Assembly Bio, Gilead, Proteus Digital Health• Scientific advisor/Consultant: The terms of these arrangements are being managed by the Johns Hopkins University in accordance with its conflict of interest policies: AbbVie, Arbutus, GileadOFN, JH, SHM, SDM, GDK, DT, CL, OL, SCR have no conflicts of interest.